Review Article | Published:

Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

Nature Reviews Gastroenterology & Hepatology volume 10, pages 330344 (2013) | Download Citation

Abstract

NAFLD is a spectrum of progressive liver disease that encompasses simple steatosis, NASH, fibrosis and, ultimately, cirrhosis. NAFLD is recognized as the hepatic component of the metabolic syndrome, as these conditions have insulin resistance as a common pathophysiological mechanism. Therefore, NAFLD is strongly associated with type 2 diabetes mellitus and abdominal obesity. As lifestyles have become increasingly sedentary and dietary patterns have changed, the worldwide prevalence of NAFLD has increased dramatically and is projected to be the principal aetiology for liver transplantation within the next decade. Importantly, a growing body of clinical and epidemiological evidence suggests that NAFLD is associated not only with liver-related morbidity and mortality, but also with an increased risk of developing both cardiovascular disease and type 2 diabetes mellitus. This article reviews the evidence that suggests NAFLD is a multisystem disease and the factors that might determine interindividual variation in the development and progression of its major hepatic and extrahepatic manifestations (principally type 2 diabetes mellitus and cardiovascular disease).

Key points

  • NAFLD is a spectrum of progressive liver disease that includes steatosis, NASH, fibrosis, cirrhosis and hepatocellular carcinoma

  • NAFLD is a common and underdiagnosed condition that is strongly associated with features of the metabolic syndrome, particularly abdominal obesity and type 2 diabetes mellitus

  • NAFLD, and especially NASH, are associated with an increased risk of morbidity and mortality related to the liver and cardiovascular system

  • NAFLD is also associated with an increased risk of developing type 2 diabetes mellitus

  • Considerable interindividual variation exists in the severity of NAFLD and the risk of morbidity and mortality that might be influenced by a combination of genetic and environmental factors

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & How big a problem is non-alcoholic fatty liver disease? BMJ 343, d3897 (2011).

  2. 2.

    & Non-alcoholic fatty liver disease: the mist gradually clears. J. Hepatol. 48 (Suppl. 1), S104–S112 (2008).

  3. 3.

    AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 123, 1705–1725 (2002).

  4. 4.

    , , , & A position statement on NAFLD/NASH based on the EASL 2009 special conference. J. Hepatol. 53, 372–384 (2010).

  5. 5.

    et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 51, 1593–1602 (2010).

  6. 6.

    et al. Impact of fatty liver disease on health care utilization and costs in a general population: a 5-year observation. Gastroenterology 134, 85–94 (2008).

  7. 7.

    Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin. Gastroenterol. Hepatol. 2, 1048–1058 (2004).

  8. 8.

    , & The importance of fatty liver disease in clinical practice. Proc. Nutr. Soc. 69, 518–527 (2010).

  9. 9.

    , , & Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 43, 617–649 (2011).

  10. 10.

    et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 128, 1898–1906 (2005).

  11. 11.

    & Epidemiology and natural history of non-alcoholic steatohepatitis. Clin. Liver Dis. 13, 511–531 (2009).

  12. 12.

    et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55, 2005–2023 (2012).

  13. 13.

    American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of liver chemistry tests. Gastroenterology 123, 1364–1366 (2002).

  14. 14.

    et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 123, 745–750 (2002).

  15. 15.

    et al. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J. Hepatol. 51, 433–445 (2009).

  16. 16.

    et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J. Hepatol. 51, 1061–1067 (2009).

  17. 17.

    et al. Hepatic triglyceride content and its relation to body adiposity: a magnetic resonance imaging and proton magnetic resonance spectroscopy study. Gut 54, 122–127 (2005).

  18. 18.

    et al. Phenotyping murine models of non-alcoholic fatty liver disease through metabolic profiling of intact liver tissue. Clin. Sci. (Lond.) 116, 403–413 (2009).

  19. 19.

    et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J. Hepatol. 56, 234–240 (2012).

  20. 20.

    et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 37, 1286–1292 (2003).

  21. 21.

    , & Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 34, 274–285 (2011).

  22. 22.

    et al. Liver biopsy findings from healthy potential living liver donors: reasons for disqualification, silent diseases and correlation with liver injury tests. J. Hepatol. 50, 501–510 (2009).

  23. 23.

    et al. Preoperative donor liver biopsy for adult living donor liver transplantation: risks and benefits. Liver Transpl. 11, 980–986 (2005).

  24. 24.

    et al. Living donor liver transplantation: histological abnormalities found on liver biopsies of apparently healthy potential donors. J. Gastroenterol. Hepatol. 21, 381–383 (2006).

  25. 25.

    , , & One hundred consecutive hepatic biopsies in the workup of living donors for right lobe liver transplantation. Liver Transpl. 8, 1114–1122 (2002).

  26. 26.

    et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40, 1387–1395 (2004).

  27. 27.

    et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am. J. Physiol. Endocrinol. Metab. 288, E462–E468 (2005).

  28. 28.

    et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30, 1212–1218 (2007).

  29. 29.

    et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet. Med. 22, 1141–1145 (2005).

  30. 30.

    et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 140, 124–131 (2011).

  31. 31.

    et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 34, 1139–1144 (2011).

  32. 32.

    , , & The epidemiology of fatty liver. Eur. J. Gastroenterol. Hepatol. 16, 1087–1093 (2004).

  33. 33.

    & Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hepatology 12, 1106–1110 (1990).

  34. 34.

    , & Liver pathology in diabetes mellitus and morbid obesity. Clinical, pathological, and biochemical considerations. Pathol. Annu. 24, 275–302 (1989).

  35. 35.

    & Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment. Nat. Rev. Endocrinol. 7, 456–465 (2011).

  36. 36.

    et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37, 917–923 (2003).

  37. 37.

    & Fatty liver: a novel component of the metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 28, 27–38 (2008).

  38. 38.

    et al. From the metabolic syndrome to NAFLD or vice versa? Dig. Liver Dis. 42, 320–330 (2010).

  39. 39.

    , , , & Liver fat in the metabolic syndrome. J. Clin. Endocrinol. Metab. 92, 3490–3497 (2007).

  40. 40.

    et al. Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care 31, 165–169 (2008).

  41. 41.

    et al. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49, 749–758 (2000).

  42. 42.

    Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221–1231 (2002).

  43. 43.

    et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am. J. Gastroenterol. 105, 1567–1573 (2010).

  44. 44.

    et al. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care 22, 756–761 (1999).

  45. 45.

    et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia 51, 444–450 (2008).

  46. 46.

    et al. Relationship between kidney function and liver histology in subjects with nonalcoholic steatohepatitis. Clin. J. Am. Soc. Nephrol. 5, 2166–2171 (2010).

  47. 47.

    et al. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and retinopathy in type 1 diabetic patients. Diabetologia 53, 1341–1348 (2010).

  48. 48.

    Elevated serum γ-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer - a narrative review. Clin. Chem. Lab. Med. 48, 147–157 (2010).

  49. 49.

    et al. Gamma-glutamyltransferase and diabetes--a 4 year follow-up study. Diabetologia 46, 359–364 (2003).

  50. 50.

    et al. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 54, 3140–3147 (2005).

  51. 51.

    et al. Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism 57, 387–392 (2008).

  52. 52.

    et al. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 135, 1935–1944 (2008).

  53. 53.

    et al. Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care 31, 1138–1143 (2008).

  54. 54.

    , , , & NAFLD as a risk factor for the development of diabetes and the metabolic syndrome: an eleven-year follow-up study. Am. J. Gastroenterol. 104, 861–867 (2009).

  55. 55.

    et al. Alanine aminotransferase, γ-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 32, 741–750 (2009).

  56. 56.

    et al. The association of fatty liver and diabetes risk. J. Epidemiol. 13, 15–21 (2003).

  57. 57.

    et al. Effects of nonalcoholic fatty liver disease on the development of metabolic disorders. J. Gastroenterol. Hepatol. 22, 1086–1091 (2007).

  58. 58.

    , , , & Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care 30, 2940–2944 (2007).

  59. 59.

    , , , & Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabet. Med. 25, 476–481 (2008).

  60. 60.

    et al. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. J. Gastroenterol. Hepatol. 25, 352–356 (2010).

  61. 61.

    & Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. J. Clin. Endocrinol. Metab. 96, 1093–1097 (2011).

  62. 62.

    et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study. Diabetes Care 34, 727–729 (2011).

  63. 63.

    , , & Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 35, 717–722 (2012).

  64. 64.

    et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44, 865–873 (2006).

  65. 65.

    , & Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 363, 1341–1350 (2010).

  66. 66.

    , , & Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur. Heart J. 33, 1190–1200 (2012).

  67. 67.

    , , , & Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link? J. Hepatol. 54, 1020–1029 (2011).

  68. 68.

    , , , & Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J. Hepatol. 50, 1029–1034 (2009).

  69. 69.

    et al. Elevated serum uric acid levels are associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in the United States: Liver ultrasound data from the National Health and Nutrition Examination Survey. Metabolism 62, 392–399 (2013).

  70. 70.

    , , , & Hyperuricemia is associated with histological liver damage in patients with non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 34, 757–766 (2011).

  71. 71.

    et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 17, 517–524 (2007).

  72. 72.

    , , & High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. Hepatology 39, 1458–1459 (2004).

  73. 73.

    et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 64, 679–683 (2006).

  74. 74.

    et al. Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J. Clin. Endocrinol. Metab. 90, 3498–3504 (2005).

  75. 75.

    et al. Nonalcoholic fatty liver disease as a contributor to hypercoagulation and thrombophilia in the metabolic syndrome. Semin. Thromb. Hemost. 35, 277–287 (2009).

  76. 76.

    , , & Hypercoagulation and thrombophilia in nonalcoholic fatty liver disease: mechanisms, human evidence, therapeutic implications, and preventive implications. Semin. Liver Dis. 32, 39–48 (2012).

  77. 77.

    et al. Circulating levels and hepatic expression of molecular mediators of atherosclerosis in nonalcoholic fatty liver disease. Atherosclerosis 209, 585–591 (2010).

  78. 78.

    et al. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am. J. Gastroenterol. 103, 1372–1379 (2008).

  79. 79.

    et al. Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease. Atherosclerosis 218, 378–385 (2011).

  80. 80.

    et al. Gene expression in human NAFLD. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G1281–G1287 (2008).

  81. 81.

    et al. Genes involved in fatty acid partitioning and binding, lipolysis, monocyte/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects. Diabetes 56, 2759–2765 (2007).

  82. 82.

    et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 42, 473–480 (2005).

  83. 83.

    et al. Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease. Hepatology 52, 1643–1651 (2010).

  84. 84.

    et al. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J. Hypertens. 28, 1699–1707 (2010).

  85. 85.

    et al. The relationship between arterial stiffness and nonalcoholic fatty liver disease. Dig. Dis. Sci. 57, 196–203 (2012).

  86. 86.

    et al. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men: role of visceral fat accumulation. Diabetes Care 27, 2498–2500 (2004).

  87. 87.

    et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: a case-control study. Arterioscler. Thromb. Vasc. Biol. 25, 1045–1050 (2005).

  88. 88.

    et al. Hepatic steatosis is associated with an increased risk of carotid atherosclerosis. World J. Gastroenterol. 11, 1848–1853 (2005).

  89. 89.

    et al. Carotid artery intima-media thickness in nonalcoholic fatty liver disease. Am. J. Med. 121, 72–78 (2008).

  90. 90.

    et al. Fatty liver index, γ-glutamyltransferase, and early carotid plaques. Hepatology 55, 1406–1415 (2012).

  91. 91.

    & Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J. Hepatol. 49, 600–607 (2008).

  92. 92.

    et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 29, 1325–1330 (2006).

  93. 93.

    et al. Assessment of endothelial function in patients with nonalcoholic fatty liver disease. Endocrine 43, 100–107 (2013).

  94. 94.

    , , & Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. Diabetes Care 35, 2359–2364 (2012).

  95. 95.

    et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J. Clin. Gastroenterol. 40, 949–955 (2006).

  96. 96.

    et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr. Metab. Cardiovasc. Dis. 19, 646–653 (2009).

  97. 97.

    et al. Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 35, 389–395 (2012).

  98. 98.

    et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J. Hepatol. .

  99. 99.

    et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47, 51–58 (2008).

  100. 100.

    et al. Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J. Am. Coll. Cardiol. 56, 225–233 (2010).

  101. 101.

    et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 291, E282–E290 (2006).

  102. 102.

    & Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin. Gastroenterol. Hepatol. 10, 646–650 (2012).

  103. 103.

    et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 343, d6891 (2011).

  104. 104.

    , & Sonographic fatty liver, overweight and ischemic heart disease. World J. Gastroenterol. 11, 4838–4842 (2005).

  105. 105.

    et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J. Hepatol. 53, 713–718 (2010).

  106. 106.

    , , , & Liver: an alarm for the heart? Liver Int. 27, 891–894 (2007).

  107. 107.

    , , , & Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 254, 393–400 (2010).

  108. 108.

    et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut 60, 1721–1727 (2011).

  109. 109.

    et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 116, 1413–1419 (1999).

  110. 110.

    et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 53, 750–755 (2004).

  111. 111.

    et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin. Gastroenterol. Hepatol. 7, 234–238 (2009).

  112. 112.

    et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 129, 113–121 (2005).

  113. 113.

    et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 51, 595–602 (2010).

  114. 114.

    , , & Prognosis of patients with liver cirrhosis and spontaneous bacterial peritonitis. Hepatogastroenterology 50, 2133–2136 (2003).

  115. 115.

    et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J. Gastroenterol. 13, 1579–1584 (2007).

  116. 116.

    et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 30, 2119–2121 (2007).

  117. 117.

    et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum γ-glutamyl transpeptidase levels. Hepatology 50, 1403–1411 (2009).

  118. 118.

    , , , & Natural course of nonalcoholic fatty liver disease in southern China: a prospective cohort study. J. Dig. Dis. 13, 153–160 (2012).

  119. 119.

    et al. Gamma-glutamyltransferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler. Thromb. Vasc. Biol. 27, 2729–2735 (2007).

  120. 120.

    et al. The Framingham risk score and heart disease in nonalcoholic fatty liver disease. Liver Int. 32, 945–950 (2012).

  121. 121.

    et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11, 74–80 (1990).

  122. 122.

    et al. Liver fibrosis in overweight patients. Gastroenterology 118, 1117–1123 (2000).

  123. 123.

    , & The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am. J. Gastroenterol. 98, 2042–2047 (2003).

  124. 124.

    , , & Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J. Clin. Pathol. 55, 689–692 (2002).

  125. 125.

    , , & The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J. Hepatol. 42, 132–138 (2005).

  126. 126.

    Nonalcoholic steatohepatitis: a study of 49 patients. Hum. Pathol. 20, 594–598 (1989).

  127. 127.

    , , & Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 107, 1103–1109 (1994).

  128. 128.

    , , , & Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 40, 820–826 (2004).

  129. 129.

    et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 29, 664–669 (1999).

  130. 130.

    , & Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology 32, 689–692 (2000).

  131. 131.

    , , & Newly diagnosed diabetes mellitus as a risk factor for serious liver disease. CMAJ 182, 526–531 (2010).

  132. 132.

    , , & Population-based risk factors and resource utilization for HCC: US perspective. Curr. Med. Res. Opin. 26, 2183–2191 (2010).

  133. 133.

    The global health burden of infection-associated cancers in the year 2002. Int. J. Cancer 118, 3030–3044 (2006).

  134. 134.

    , & Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 51, 1820–1832 (2010).

  135. 135.

    et al. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J. Gastroenterol. 44 (Suppl. 19), 89–95 (2009).

  136. 136.

    et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 51, 1972–1978 (2010).

  137. 137.

    & Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132, 2557–2576 (2007).

  138. 138.

    , , & Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N. Engl. J. Med. 348, 1625–1638 (2003).

  139. 139.

    , , & Obesity and cancer risk: a Danish record-linkage study. Eur. J. Cancer 30A, 344–350 (1994).

  140. 140.

    , & Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J. Clin. Oncol. 23, 4742–4754 (2005).

  141. 141.

    , & Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126, 460–468 (2004).

  142. 142.

    et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch. Pathol. Lab. Med. 132, 1761–1766 (2008).

  143. 143.

    & Increased risk of cardiovascular disease and chronic kidney disease in NAFLD. Nat. Rev. Gastroenterol. Hepatol. 9, 372–381 (2012).

  144. 144.

    & Mechanisms linking obesity, chronic kidney disease, and fatty liver disease: the roles of fetuin-A, adiponectin, and AMPK. J. Am. Soc. Nephrol. 21, 406–412 (2010).

  145. 145.

    Liver fat in the pathogenesis of insulin resistance and type 2 diabetes. Dig. Dis. 28, 203–209 (2010).

  146. 146.

    & The adipocyte as an active participant in energy balance and metabolism. Gastroenterology 132, 2103–2115 (2007).

  147. 147.

    , & Obesity, inflammation, and insulin resistance. Gastroenterology 132, 2169–2180 (2007).

  148. 148.

    , & Causes and metabolic consequences of fatty liver. Endocr. Rev. 29, 939–960 (2008).

  149. 149.

    , & Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology 51, 679–689 (2010).

  150. 150.

    & Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol. Metab. 19, 371–379 (2008).

  151. 151.

    et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115, 1343–1351 (2005).

  152. 152.

    et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology 45, 1366–1374 (2007).

  153. 153.

    , & Apoptosis and necrosis in the liver: a tale of two deaths? Hepatology 43, S31–S44 (2006).

  154. 154.

    et al. Impact of pan-caspase inhibition in animal models of established steatosis and non-alcoholic steatohepatitis. J. Hepatol. 53, 542–550 (2010).

  155. 155.

    et al. Apoptosis in experimental NASH is associated with p53 activation and TRAIL receptor expression. J. Gastroenterol. Hepatol. 24, 443–452 (2009).

  156. 156.

    Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. J. Clin. Invest. 117, 539–548 (2007).

  157. 157.

    , & Genetics of alcoholic and nonalcoholic fatty liver disease. Semin. Liver Dis. 31, 128–146 (2011).

  158. 158.

    & Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int. J. Exp. Pathol. 87, 1–16 (2006).

  159. 159.

    & Genome-wide association studies in type 2 diabetes. Curr. Diab. Rep. 9, 164–171 (2009).

  160. 160.

    , & Genetic modifiers of non-alcoholic fatty liver disease progression. Biochim. Biophysica Acta 1812, 1557–1566 (2011).

  161. 161.

    et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet. 40, 1461–1465 (2008).

  162. 162.

    et al. Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease. Gastroenterology 139, 1567–1576 (2010).

  163. 163.

    et al. Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits. PLoS Genet. 7, e1001324 (2011).

  164. 164.

    et al. Genome-wide association analysis confirms importance of PNPLA3 and identifies novel variants associated with histologically progressive fibrosing steatohepatitis in NAFLD [abstract 146]. Hepatology 56 (Suppl.), 265A–266A (2012).

  165. 165.

    et al. Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese. PLoS ONE 7, e38322 (2012).

  166. 166.

    et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51, 1209–1217 (2010).

  167. 167.

    et al. A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans. Diabetologia 52, 1056–1060 (2009).

  168. 168.

    et al. A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. J. Lipid Res. 50, 2111–2116 (2009).

  169. 169.

    et al. Dissociation between fatty liver and insulin resistance in humans carrying a variant of the patatin-like phospholipase 3 gene. Diabetes 58, 2616–2623 (2009).

  170. 170.

    , , , & The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52, 894–903 (2010).

  171. 171.

    et al. Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis. J. Hepatol. 40, 781–786 (2004).

  172. 172.

    et al. The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies. J. Hepatol. 56, 448–454 (2012).

  173. 173.

    et al. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J. Hepatol. 46, 915–920 (2007).

  174. 174.

    et al. Polymorphism of the PEMT gene and susceptibility to nonalcoholic fatty liver disease (NAFLD). Faseb J. 19, 1266–1271 (2005).

  175. 175.

    et al. A germline DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene and is associated with increased prostate cancer risk. Cancer Res. 65, 1213–1222 (2005).

  176. 176.

    et al. The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. Gastroenterology 135, 282–291 (2008).

  177. 177.

    , , & Unravelling the pathogenesis of fatty liver disease: patatin-like phospholipase domain-containing 3 protein. Curr. Opin. Lipidol. 21, 247–252 (2010).

  178. 178.

    et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 306, 1383–1386 (2004).

  179. 179.

    et al. A common variant in the adiponutrin gene influences liver enzyme values. J. Med. Genet. 47, 116–119 (2010).

  180. 180.

    et al. Chronic overexpression of PNPLA3I148M in mouse liver causes hepatic steatosis. J. Clin. Invest. 122, 4130–4144 (2012).

  181. 181.

    , & Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J. Hepatol. 56, 255–266 (2012).

  182. 182.

    et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut 60, 1278–1283 (2011).

  183. 183.

    & Cholesterol and nonalcoholic fatty liver disease: Renewed focus on an old villain. Hepatology 56, 1995–1998 (2012).

  184. 184.

    et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J. Hepatol. 48, 993–999 (2008).

  185. 185.

    , , , & The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat. Rev. Gastroenterol. Hepatol. 7, 251–264 (2010).

  186. 186.

    et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51, 1961–1971 (2010).

  187. 187.

    et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J. Hepatol. 48, 983–992 (2008).

  188. 188.

    et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J. Hepatol. 47, 571–579 (2007).

  189. 189.

    et al. Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 50, 1094–1104 (2009).

  190. 190.

    , & Metabolic observations in patients with jejunocolic shunts. Am. J. Surg. 106, 273–289 (1963).

  191. 191.

    Liver dysfunction after intestinal bypass. JAMA 236, 1693–1694 (1976).

  192. 192.

    et al. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 48, 206–211 (2001).

  193. 193.

    et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49, 1877–1887 (2009).

  194. 194.

    et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J. Inflamm. (Lond.) 7, 15 (2010).

  195. 195.

    Genomic approaches to studying the human microbiota. Nature 489, 250–256 (2012).

  196. 196.

    & The role of the gut microbiota in nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 7, 691–701 (2010).

  197. 197.

    & Functional interactions between the gut microbiota and host metabolism. Nature 489, 242–249 (2012).

  198. 198.

    et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 482, 179–185 (2012).

  199. 199.

    et al. Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: Possible pathogenetic role in NASH. Hepatology 47, 1167–1177 (2008).

  200. 200.

    et al. Genetic variation in the ADIPOR2 gene is associated with liver fat content and its surrogate markers in three independent cohorts. Eur. J. Endocrinol. 160, 593–602 (2009).

  201. 201.

    et al. Association between angiotensin II type 1 receptor polymorphisms and the occurrence of nonalcoholic fatty liver disease. Liver Int. 29, 1078–1085 (2009).

  202. 202.

    et al. Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. J. Hepatol. 39, 967–971 (2003).

  203. 203.

    et al. Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease. N. Engl. J. Med. 362, 1082–1089 (2010).

  204. 204.

    et al. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage in patients with nonalcoholic fatty liver. J. Hepatol. 55, 1409–1414 (2012).

  205. 205.

    et al. Association of apolipoprotein E polymorphisms in patients with non-alcoholic steatohepatitis. Dig. Dis. Sci. 53, 3218–3224 (2008).

  206. 206.

    et al. Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease. Dig. Dis. Sci. 52, 3399–3403 (2007).

  207. 207.

    , , , & Polymorphisms of MRP2 (ABCC2) are associated with susceptibility to nonalcoholic fatty liver disease. J. Nutr. Biochem. 20, 765–770 (2009).

  208. 208.

    , , , & Genetic evidence for a role of gut flora in the pathogenesis of NASH in humans. Hepatology 44 (Suppl. 1), 261A (2006).

  209. 209.

    et al. Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut 59, 267–273 (2010).

  210. 210.

    et al. Genetic polymorphisms in non-alcoholic fatty liver disease: interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis. Dig. Liver Dis. 41, 823–828 (2009).

  211. 211.

    et al. Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 25, 357–361 (2010).

  212. 212.

    et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114, 311–318 (1998).

  213. 213.

    et al. HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis. Hepatology 46, 723–729 (2007).

  214. 214.

    et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 39, 179–187 (2004).

  215. 215.

    , , , & The mitochondrial superoxide dismutase 2 (SOD2) targeting sequence polymorphism is associated with fibrotic NAFLD: consistent evidence from case-control and intra-familial allelic association studies. Hepatology 46, 760A (2007).

  216. 216.

    et al. Methylenetetrahydrofolate reductase gene polymorphisms in patients with nonalcoholic steatohepatitis (NASH). Cell Biochem. Funct. 26, 291–296 (2008).

  217. 217.

    et al. The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet. Genomics 20, 1–8 (2010).

  218. 218.

    et al. Transcription factor 7-like 2 polymorphism modulates glucose and lipid homeostasis, adipokine profile, and hepatocyte apoptosis in NASH. Hepatology 49, 426–435 (2009).

  219. 219.

    et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 122, 274–280 (2002).

Download references

Acknowledgements

Q. M. Anstee would like to acknowledge the support of a Clinical Senior Lectureship Award from the Higher Education Funding Council for England (HEFCE). Q. M. Anstee and C. P. Day are members of the European Union FP7-funded Fatty Liver Inhibition of Progression (FLIP) Consortium.

Author information

Affiliations

  1. Liver Research Group, Institute of Cellular Medicine, The Medical School, Newcastle University, Framlington Place, Newcastle-upon-Tyne NE2 4HH, UK

    • Quentin M. Anstee
    •  & Christopher P. Day
  2.  Department of Medicine, Section of Endocrinology, Diabetes and Metabolism, University and Azienda Ospedaliera Universitaria Integrata of Verona, Ospedale Civile Maggiore, Piazzale Stefani 1, 37126 Verona, Italy

    • Giovanni Targher

Authors

  1. Search for Quentin M. Anstee in:

  2. Search for Giovanni Targher in:

  3. Search for Christopher P. Day in:

Contributions

All authors contributed equally to all aspects of this article.

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Christopher P. Day.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrgastro.2013.41

Further reading